Detalhe da pesquisa
1.
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
Am J Hematol;
2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38751104
2.
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
Leukemia;
2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38755421
3.
PhALLCON Soars to New Heights-Faster, Stronger, but Better?
JAMA;
331(21): 1805-1806, 2024 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38722663
4.
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
Blood Adv;
2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38607410
5.
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients.
Leukemia;
2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538860
6.
Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?
Blood Rev;
65: 101184, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493006
7.
Race/ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia.
J Natl Cancer Inst;
2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38518098
8.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw;
22(1): 43-69, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394770
9.
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Leukemia;
38(4): 762-768, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38378841
10.
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Lancet Oncol;
25(3): 388-399, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423051
11.
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols.
Leukemia;
38(3): 482-490, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38177437
12.
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Leukemia;
38(3): 475-481, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38287132
13.
Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
Blood Adv;
8(4): 978-990, 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197938
14.
Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Blood Adv;
8(1): 23-36, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37389830
15.
Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia.
Haematologica;
109(4): 1046-1052, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37560812
16.
Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing.
JCO Oncol Pract;
20(2): 220-227, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37683132
17.
CML and the WHO: Why?
J Clin Oncol;
42(9): 984-986, 2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38086008
18.
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
Blood Adv;
8(3): 591-602, 2024 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38052038
19.
Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow.
Mod Pathol;
37(1): 100352, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839675
20.
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia.
Blood Cancer J;
13(1): 192, 2023 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123559